PDCD1 and metastatic melanoma: In a study on metastatic melanoma described above, loss-of-function mutations in genes involved in IFNγ pathway (e.g., JAK1 and JAK2) are found associated with relapse of patients who have shown initial response to anti-PD-1 therapy.